# Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer

> **NCT02483104** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 9 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** veliparib
- **DRUG:** carboplatin
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT02483104
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2016-03
- **Final completion:** 2016-07
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2017-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02483104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02483104, "Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02483104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*